ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunnee, T
Right arrow Articles by Kunkel, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunnee, T
Right arrow Articles by Kunkel, G
Eur Respir J 1992; 5: 982-985
Copyright © ERS Journals Ltd 1992

Clinical Trial

Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma

T Brunnee, R Engelstatter, VW Steinijans, and G Kunkel

Zardaverine is a newly developed selective phosphodiesterase III and IV inhibitor. This study investigates the bronchodilatory properties of zardaverine, administered by inhalation. Twelve patients with reversible bronchial obstruction (increase in forced expiratory volume in one second (change FEV1 % predicted) at least 15% after 200 micrograms salbutamol, median age 31 yrs, range 21-54 years) entered the double-blind, crossover study. Four puffs of either zardaverine (total dose 6 mg) or placebo were inhaled at 15 min intervals. Pulmonary function (specific airway conductance (sGaw) and FEV1 was measured by body plethysmography at regular intervals (5 and 12 min after each puff and, in addition, 30, 60, 120, 180 and 240 min after the last puff). Compared to placebo, sGaw and FEV1 increased significantly during the first hour of repeated inhalations, but not during the entire observation period of almost 5 h. The maximum mean difference between zardaverine and placebo for FEV1 was 0.3 l or 12% and occurred approximately 1 h after inhalation of the first puff. In seven patients FEV1 increased by > 15%. The duration of action varied considerably between patients. Three patients complained of side-effects (headache, drowsiness, vertigo, nausea), and one of these dropped out of the study due to vomiting. We conclude that inhalational administration of zardaverine has a modest and short-lasting bronchodilating activity.


This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
M. A. Giembycz
Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. MYOU, M. FUJIMURA, Y. KAMIO, Y. ISHIURA, H. TACHIBANA, T. HIROSE, T. HASHIMOTO, and T. MATSUDA
Bronchodilator Effect of Inhaled Olprinone, a Phosphodiesterase 3 Inhibitor, in Asthmatic Patients
Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 817 - 820.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. B. Dowling, M. Johnson, P. J. Cole, and R. Wilson
The Effect of Rolipram, a Type IV Phosphodiesterase Inhibitor, on Pseudomonas aeruginosa Infection of Respiratory Mucosa
J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1565 - 1571.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. J. TORPHY
Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the European Respiratory Society.